ENLIVEN THERAPEUTICS INC (ELVN) Stock Price, Quote, News and Overview
NASDAQ:ELVN - Nasdaq - US29337E1029 - Common Stock - Currency: USD
ELVN Quote, Performance and Key Statistics
21.8
+0.33 (+1.54%)
The current stock price of ELVN is 21.8 USD. In the past month the price decreased by -1.09%. In the past year, price increased by 31.88%.
ELVN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ELVN
Company Profile
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. The company is headquartered in Boulder, Colorado and currently employs 57 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Company Info
ENLIVEN THERAPEUTICS INC
6200 Lookout Road
Boulder COLORADO US
Employees: 52
Company Website: https://www.enliventherapeutics.com/
Investor Relations: https://ir.enliventherapeutics.com/
Phone: 17206478519
ENLIVEN THERAPEUTICS INC / ELVN FAQ
What is the stock price of ENLIVEN THERAPEUTICS INC today?
The current stock price of ELVN is 21.8 USD. The price increased by 1.54% in the last trading session.
What is the ticker symbol for ENLIVEN THERAPEUTICS INC stock?
The exchange symbol of ENLIVEN THERAPEUTICS INC is ELVN and it is listed on the Nasdaq exchange.
On which exchange is ELVN stock listed?
ELVN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ENLIVEN THERAPEUTICS INC stock?
14 analysts have analysed ELVN and the average price target is 38.61 USD. This implies a price increase of 77.13% is expected in the next year compared to the current price of 21.8. Check the ENLIVEN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ENLIVEN THERAPEUTICS INC worth?
ENLIVEN THERAPEUTICS INC (ELVN) has a market capitalization of 1.07B USD. This makes ELVN a Small Cap stock.
How many employees does ENLIVEN THERAPEUTICS INC have?
ENLIVEN THERAPEUTICS INC (ELVN) currently has 52 employees.
What are the support and resistance levels for ENLIVEN THERAPEUTICS INC (ELVN) stock?
ENLIVEN THERAPEUTICS INC (ELVN) has a support level at 21.72 and a resistance level at 21.87. Check the full technical report for a detailed analysis of ELVN support and resistance levels.
Should I buy ENLIVEN THERAPEUTICS INC (ELVN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ELVN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ELVN, evaluating the profitability, health, valuation and growth aspects
- ENLIVEN THERAPEUTICS INC (ELVN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENLIVEN THERAPEUTICS INC (ELVN) Sales and EPS estimates to see what analysts future expectations are.
- ENLIVEN THERAPEUTICS INC (ELVN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENLIVEN THERAPEUTICS INC (ELVN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENLIVEN THERAPEUTICS INC (ELVN) Stock Chart to make your own analysis
- ENLIVEN THERAPEUTICS INC (ELVN) Latest news and press-releases to stay up to date.
Does ENLIVEN THERAPEUTICS INC (ELVN) stock pay dividends?
ELVN does not pay a dividend.
When does ENLIVEN THERAPEUTICS INC (ELVN) report earnings?
ENLIVEN THERAPEUTICS INC (ELVN) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of ENLIVEN THERAPEUTICS INC (ELVN)?
ENLIVEN THERAPEUTICS INC (ELVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
What is the Short Interest ratio of ENLIVEN THERAPEUTICS INC (ELVN) stock?
The outstanding short interest for ENLIVEN THERAPEUTICS INC (ELVN) is 18.88% of its float. Check the ownership tab for more information on the ELVN short interest.
ELVN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ELVN. When comparing the yearly performance of all stocks, ELVN is one of the better performing stocks in the market, outperforming 76.97% of all stocks.
ELVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELVN. No worries on liquidiy or solvency for ELVN as it has an excellent financial health rating, but there are worries on the profitability.
ELVN Financial Highlights
Over the last trailing twelve months ELVN reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS decreased by -161.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.9% | ||
| ROE | -29.55% | ||
| Debt/Equity | 0 |
ELVN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to ELVN. The Buy consensus is the average rating of analysts ratings from 14 analysts.